Clinical Trial Update: Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating infectivity, safety, and immunogenicity of two recombinant, live-attenuated B/HPIV3 vectored vaccines expressing the fusion glycoprotei…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Human Parainfluenza Virus Type Infection

Drugs mentioned

• B/HPIV3 vectored HMPV vaccine candidate 1
• B/HPIV3 vectored HMPV vaccine candidate 2

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Human Metapneumovirus, Human Parainfluenza Virus Type 3 | Phase 1 | Status: COMPLETED